MTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.
Ontology highlight
ABSTRACT: Effective treatments for recurrent/metastatic human papillomavirus-positive (HPV+) head and neck squamous cell cancer (HNSCC) are limited. To aid treatment development, we characterized a novel murine model of recurrent/metastatic HPV+ HNSCC. Further analysis of the parental tumor cell line and its four recurrent/metastatic derivatives led to preclinical testing of an effective treatment option for this otherwise fatal disease. Reverse phase protein arrays identified key signaling cascades in the parental and recurrent/metastatic cell lines. While protein expression profiles differed among the recurrent/metastatic cell lines, activated proteins associated with the mTOR signaling cascade were a commonality. Based on these data, mTOR inhibition was evaluated as an adjuvant treatment for recu
SUBMITTER: Coppock JD
PROVIDER: S-EPMC5029697 | biostudies-literature | 2016 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA